Tongji Hospital

Company snapshot

Tongji Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include 2019-nCoV Pneumonia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tongji Hospital. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Tongji Hospital.

1. May 26, 2026 Clinical update

   ASC09F+Oseltamivir — Phase 3

View all clinical trial activity →

• What is Tongji Hospital?

  Tongji Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include 2019-nCoV Pneumonia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sour

• Is Tongji Hospital publicly traded?

  Tongji Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Tongji Hospital develop or market?

  We link 1 drug profile(s) where Tongji Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tongji-hospital#company-drugs.

• What are the latest developments for Tongji Hospital?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tongji Hospital focus on?

  Tongji Hospital focuses on 2019-nCoV Pneumonia based on our analysis of their pipeline programs and drug development activities.